Laboratory automation Market Outlook 2026–2034: Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast — A Meticulous Next™ Foresight Brief

This Meticulous Next™ brief examines laboratory automation, the use of liquid handlers, modular robotic workcells, orchestration software and cloud laboratories to run experiments at higher volume and with less manual work. It tests how fast AI-driven orchestration and low-cost modular robots spread beyond large screening laboratories, and which participants capture value among instrument suppliers, robotics and cloud laboratory developers, pharmaceutical companies and contract research organisations.

Orchestration software is becoming the point of competition. At SLAS2026 in February 2026, HighRes, a laboratory automation supplier owned by Axel Johnson Inc., launched a new brand and an AI platform with laboratory assistants and agents, robotic perception that verifies steps and recovers from errors, and digital twins that test workflows before they are built. The company announced a partnership with Opentrons Labworks to connect modular robots to its CellarioOS orchestration software. The conclusion is that suppliers are shifting value from hardware to software that plans, checks and repeats experiments, which favours owners of large installed bases of instruments.

Modular robots are moving into large organisations. Merck unveiled an Automated Assay Workstation built on Opentrons technology in August 2025, reported by BioSpectrum Asia, to take repetitive manual experiments off researchers and give consistent results across settings. Opentrons platforms have been reported in tens of thousands of laboratories. The conclusion is that low-cost modular systems are being adopted by the largest suppliers as a standard layer, which lowers the entry price of automation for smaller laboratories.

Autonomous laboratories show the ceiling and the debate. The A-Lab at Lawrence Berkeley National Laboratory reported in Nature in November 2023 that it made 41 of 58 target compounds in 17 days, and the novelty of some materials was later questioned. Cloud laboratories such as Emerald Cloud Lab offer remote experiment execution to pharmaceutical and biotechnology customers. The conclusion is that fully autonomous work is proven for narrow workflows, and the broader market grows through partial automation of routine assays.

The brief treats laboratory automation as an accelerating signal with an eight year horizon to 2034. It identifies which applications, regions and operators scale first and what each means for suppliers, developers, pharmaceutical companies and research organisations. It is a focused 102-page decision brief that presents an indicative trajectory rather than a segmented market model.

Laboratory automation uses robots, instruments and software to prepare samples, run assays and capture data with limited manual work.

Liquid handlers and modular robotic workcells perform the physical steps, orchestration software schedules instruments and workflows, and digital twins test workflows before deployment.

AI agents plan and adjust experiments, and robotic perception checks steps and recovers from errors.

Uses are drug discovery and screening, genomics, synthetic biology, and increasingly routine assays in clinical and academic laboratories.

The limits are capital cost, integration effort, limited flexibility of fixed workflows and fragmented standards between vendors. The period turns on whether orchestration software makes automation flexible enough for varied research work.

The laboratory automation market, covering liquid handlers, robotic workcells, orchestration software and cloud laboratory services used in high-throughput biology, is valued at USD 6.5–9.0 billion in 2026 and is projected to reach USD 13.93–19.29 billion by 2034, at a CAGR of 10%.

The 2026 base rests on liquid handlers, robotic workcells, orchestration software and cloud laboratory services bought by pharmaceutical, biotechnology, contract research and academic laboratories. Growth then follows adoption of AI orchestration, modular robots and remote laboratories.

The forecast is sensitive to research funding, pharmaceutical spending and integration cost. Regionally, North America leads on installed systems and cloud laboratories, Europe on instrument suppliers, and Asia-Pacific on screening capacity and contract research.

Base case.

The base case assumes steady research and pharmaceutical spending and AI orchestration in new systems by 2030, giving the inflection in 2030.

Accelerated case.

An accelerated case assumes open interfaces spread quickly and modular robots reach most mid-size laboratories, bringing the inflection to 2028 and lifting the 2034 value to the top of the range.

Delayed case.

A delayed case assumes tight research budgets and slow integration, holding growth at the bottom of the range.

Growth drivers

• Drug discovery and screening volumes.
• AI driven experiment design.
• Skilled labour shortages and reproducibility needs.
• Low-cost modular robots.

Enablers

• Instrument and software partnerships.
• Cloud and remote laboratory access.
• Open interfaces and standards.
• Research funding for autonomous laboratories.

Restraints and barriers

• Capital cost and integration effort.
• Limited flexibility of fixed workflows.
• Skills for programming and maintenance.
• Fragmented standards between vendors.

The direction of laboratory automation is set by the need for reproducible and higher-volume experiments, standards and data requirements, AI agents, robotics and perception, partnering among pharmaceutical companies, contract research organisations and instrument suppliers, and system and labour cost.

The key participants in laboratory automation include Thermo Fisher Scientific Inc., Danaher Corporation, Agilent Technologies, Inc., Tecan Group Ltd., Hamilton Company, Revvity, Inc., Opentrons Labworks Inc., Axel Johnson Inc., Emerald Cloud Lab, Inc., Automata Technologies Ltd, Waters Corporation, Eppendorf SE, Sartorius AG, Bio-Rad Laboratories, Inc., Merck KGaA, BICO Group AB, Ginkgo Bioworks Holdings, Inc., Azenta, Inc., Mettler-Toledo International Inc., Shimadzu Corporation, Eli Lilly and Company, Bayer AG, Novartis AG, AstraZeneca PLC, Pfizer Inc., Charles River Laboratories International, Inc., WuXi AppTec Co., Ltd., Lawrence Berkeley National Laboratory, University of Toronto, Stanford University, Massachusetts Institute of Technology, Broad Institute, National Institutes of Health, Society for Laboratory Automation and Screening, Clinical and Laboratory Standards Institute, International Organization for Standardization, U.S. Food and Drug Administration, European Medicines Agency, Medicines and Healthcare products Regulatory Agency, National Medical Products Administration and Pharmaceuticals and Medical Devices Agency.

The brief profiles representative participants in each archetype and assesses which are positioned to lead as laboratory automation matures.

Thermo Fisher Scientific, Danaher, Agilent Technologies, Tecan, Hamilton and Revvity lead on installed instruments and workcells, Axel Johnson, through HighRes, and Opentrons Labworks lead on orchestration and modular robots, and Emerald Cloud Lab leads on remote laboratories. Eli Lilly, Bayer, Novartis and AstraZeneca are among the main pharmaceutical users. Competitive intensity is high in 2026 and rises as software becomes the point of competition.

Where value migrates.

In 2026 value sits with instrument suppliers that have large installed bases, because customers expand on systems they already run. By 2030 it moves toward orchestration and AI software providers, because software decides how much each system is used. By 2034 it settles in integrated automated and cloud laboratories that sell experiments rather than instruments. Margins hold for suppliers that own software and service contracts and narrow for providers that sell standard hardware.

The signals converge on growth led by software. Supplier launches of AI agents and digital twins in February 2026, a modular robot workstation from Merck in August 2025 and reported use of Opentrons platforms in tens of thousands of laboratories support growth, while capital cost, integration effort and fragmented standards limit the pace.

Structural limits show where progress could slow: capital cost and integration effort, limited flexibility of fixed workflows, skills for programming and maintenance, and fragmented standards. The brief therefore tracks four indicators: orchestration software launches, installed modular robots, cloud laboratory capacity, and pharmaceutical spending on automation.

Screening and genomics first, then synthetic biology and routine assays, then wider autonomous laboratories are the expected order of adoption.